Development and Validation of a Nomogram for Predicting Overall Survival In Synchronous Peritoneal Metastasis of Colorectal Cance

Wenle Chen Sun Yat-sen University Sixth A liated Hospital https://orcid.org/0000-0002-1016-7205 Zixu Yuan Sun Yat-sen University Sixth A liated Hospital Aiwen Wu Peking University Cancer Hospital: Beijing Cancer Hospital Ming Cui Peking University Cancer Hospital: Beijing Cancer Hospital Zhongyi Yue Xinxiang Medical University First A liated Hospital Qianxin Luo Sun Yat-sen University Sixth A liated Hospital Huaiming Wang A liated Gastrointestinal Hospital of Sun Yat-sen University: Sun Yat-sen University Sixth A liated Hospital Li Yang Sun Yat-sen University Sixth A liated Hospital Qiushi Dong Peking University School of Oncology: Beijing Cancer Hospital Duo Liu Sun Yat-sen University Sixth A liated Hospital Michael Hu Wang IBloomington High School South. Ying Huang Xiehe A liated Hospital of Fujian Medical University Hui Wang Sun Yat-sen University Sixth A liated Hospital Jian Cai (  caij29@mail.sysu.edu.cn ) Sun Yat-sen University Sixth A liated Hospital

[1]  Jianhua Yao,et al.  Development and Validation of an Image-based Deep Learning Algorithm for Detection of Synchronous Peritoneal Carcinomatosis in Colorectal Cancer , 2020, Annals of surgery.

[2]  G. Fontanini,et al.  Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. , 2020, The Lancet. Oncology.

[3]  Lynn Symonds,et al.  Use of perioperative chemotherapy in colorectal cancer metastatic to the liver , 2019, Gastroenterology report.

[4]  D. Morris,et al.  Long‐term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single‐institutional experience with 1225 cases , 2019, Journal of surgical oncology.

[5]  M. Pocard,et al.  A UNICANCER phase III trial of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Carcinomatosis. PRODIGE 7. , 2019, European Journal of Surgical Oncology.

[6]  J. Ji,et al.  Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Koller,et al.  Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial , 2018, Clinical colorectal cancer.

[8]  S. Jiao,et al.  A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy , 2018, Journal of Immunotherapy for Cancer.

[9]  M. Pocard,et al.  A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. , 2018, Journal of Clinical Oncology.

[10]  G. Cai,et al.  Predictive factors of synchronous colorectal peritoneal metastases: Development of a nomogram and study of its utilities using decision curve analysis. , 2018, International journal of surgery.

[11]  E. Van Cutsem,et al.  External Validation of the Prognostic Nomogram (COMPASS) for Patients with Peritoneal Carcinomatosis of Colorectal Cancer , 2017, Annals of Surgical Oncology.

[12]  H. Nakayama,et al.  Carbohydrate Antigen 19-9 Predicts Synchronous Peritoneal Carcinomatosis in Patients with Colorectal Cancer. , 2017, Anticancer research.

[13]  C. Tournigand,et al.  Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. , 2016, The Lancet. Oncology.

[14]  C. Tournigand,et al.  Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Nieboer,et al.  Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC , 2016, Annals of Surgical Oncology.

[16]  J. Esquivel.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. , 2016, Journal of gastrointestinal oncology.

[17]  C. Lepage,et al.  Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer: A Population-Based Study , 2015, Diseases of the colon and rectum.

[18]  A. Ejaz,et al.  A Nomogram to Predict Overall Survival and Disease-Free Survival After Curative Resection of Gastric Adenocarcinoma , 2015, Annals of Surgical Oncology.

[19]  S. Ikeda,et al.  An elevated preoperative serum carbohydrate antigen 19‐9 level is a significant predictor for peritoneal dissemination and poor survival in colorectal cancer , 2015, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[20]  V. Lemmens,et al.  Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  D. Morris,et al.  Synchronous liver resection with cytoreductive surgery for the treatment of liver and peritoneal metastases from colon cancer: results from an Australian centre , 2015, ANZ journal of surgery.

[22]  Li Zhang,et al.  Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Elias,et al.  Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study , 2015, Annals of Surgical Oncology.

[24]  A. Mirnezami,et al.  Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases. , 2014, World journal of gastroenterology.

[25]  Y. McConnell,et al.  Preoperative computed tomography does not predict resectability in peritoneal carcinomatosis. , 2014, American journal of surgery.

[26]  K. Shirouzu,et al.  Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis , 2014, Journal of Gastroenterology.

[27]  R. Berri,et al.  Peritoneal Surface Disease Severity Score as a predictor of resectability in the treatment of peritoneal surface malignancies. , 2014, American journal of surgery.

[28]  V. Lemmens,et al.  Incidence, Prognosis, and Treatment Options for Patients With Synchronous Peritoneal Carcinomatosis and Liver Metastases from Colorectal Origin , 2013, Diseases of the colon and rectum.

[29]  J. Coebergh,et al.  Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based study , 2011, International journal of cancer.

[30]  D. Gorden,et al.  Prognostic Value of CEA and CA 19-9 Tumor Markers Combined with Cytology from Peritoneal Fluid in Colorectal Cancer , 2009, Annals of Surgical Oncology.

[31]  G. Raj,et al.  How to build and interpret a nomogram for cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Sugarbaker,et al.  Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. , 2006, Journal of the American College of Surgeons.

[33]  P. Sugarbaker,et al.  Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Sugarbaker.  Management of peritoneal-surface malignancy: the surgeon’s role , 1999, Langenbeck's Archives of Surgery.

[35]  L. Tanoue,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[36]  PhD Peter H. Cashin MD,et al.  Comparison of Prognostic Scores for Patients with Colorectal Cancer Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy , 2013, Annals of Surgical Oncology.

[37]  M. P. Tristan D. Yan BSc,et al.  Evaluation of Preoperative Computed Tomography in Estimating Peritoneal Cancer Index in Colorectal Peritoneal Carcinomatosis , 2008, Annals of Surgical Oncology.